Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics
of CLG561 in subjects with advanced age-related macular degeneration (AMD).